Pharmaco-proteomic Platform to Evaluate Drug Interactions in Liver Transplant Patients

NCT06682325 | Recruiting

• 1 other identifier: 23I10401
• Study Type: observational
• Target: 48
• Locations: 1 country
• Sites: 3

Brief Summary

The goal of this observational study is to enhance the ability to forecast kidney failure in liver transplant patients in the ICU under multidrug treatment by developing a computer platform that integrates mathematical models of drug interactions, proteomics, and clinical data. The main outcomes it aims to develop are:

1. 1.Design the multidrug web computing platform with available information on drug pair interactions (DDIs).
2. 2.Integrate the proteomic and clinical data of liver transplant patients into the IT platform.
3. 3.Implement the multidrug web platform to predict the clinical evolution of liver transplant patients.

Conditions

Drug-drug Interaction; Liver Transplantation

Outcome Measures

Primary Outcomes (1)

• Develop a web platform that combines information on interactions between multiple drugs and proteomic and clinical profiles, to predict the clinical evolution in liver transplant patients hospitalized in the ICU

  Periodic developmental assessments will be carried out (Analysis of drug interaction graphs, Design of the interaction web platform, Integration of omics and clinical data into the web platform)

  18 to 24 months

Interventions

Multi-drug interaction OTHER

The clinical impact associated with the use of multiple drugs in liver transplant patients during their stay in ICU will be evaluated.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Liver transplant patients admitted to intensive care after surgery

You may qualify if:

• Liver transplant patients undergoing surgery at UC Christus Hospital

You may not qualify if:

• Patients on renal replacement therapy
• Patients for whom no clinical or pharmacological registry is available

Sponsors & Collaborators

• Pontificia Universidad Catolica de Chile: lead
• Universidad de Valparaiso: collaborator
• Universidad Adolfo Ibañez: collaborator

Study Sites (3)

Universidad de Valparaíso

Valparaíso, Región de Valparaíso, Chile

ACTIVE NOT RECRUITING

Hospital ClínicoUC-Christus

Santiago, Santiago Metropolitan, 8330024, Chile

RECRUITING

Pontificia Universidad Católica de Chile

Santiago, Santiago Metropolitan, Chile

ACTIVE NOT RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Blood and serum samples from patients.

Study Officials

• Nelson Barrera, PhD

  Pontificia Universidad Catolica de Chile

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Nelson Barrera, PhD

CONTACT

56987687058; nbarrerr@uc.cl

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 7, 2024
• First Posted: November 12, 2024
• Study Start: June 1, 2023
• Primary Completion: December 5, 2024
• Study Completion: May 5, 2025
• Last Updated: November 12, 2024

Record last verified: 2024-07

Data Sharing

• IPD Sharing: Will not share

Locations

CL (3)